Fulvestrant

	WikiDoc Resources for Fulvestrant
Articles
Most recent articles on Fulvestrant Most cited articles on Fulvestrant Review articles on Fulvestrant Articles on Fulvestrant in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Fulvestrant Images of Fulvestrant Photos of Fulvestrant Podcasts & MP3s on Fulvestrant Videos on Fulvestrant
Evidence Based Medicine
Cochrane Collaboration on Fulvestrant Bandolier on Fulvestrant TRIP on Fulvestrant
Clinical Trials
Ongoing Trials on Fulvestrant at Clinical Trials.gov Trial results on Fulvestrant Clinical Trials on Fulvestrant at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Fulvestrant NICE Guidance on Fulvestrant NHS PRODIGY Guidance FDA on Fulvestrant CDC on Fulvestrant
Books
Books on Fulvestrant
News
Fulvestrant in the news Be alerted to news on Fulvestrant News trends on Fulvestrant
Commentary
Blogs on Fulvestrant
Definitions
Definitions of Fulvestrant
Patient Resources / Community
Patient resources on Fulvestrant Discussion groups on Fulvestrant Patient Handouts on Fulvestrant Directions to Hospitals Treating Fulvestrant Risk calculators and risk factors for Fulvestrant
Healthcare Provider Resources
Symptoms of Fulvestrant Causes & Risk Factors for Fulvestrant Diagnostic studies for Fulvestrant Treatment of Fulvestrant
Continuing Medical Education (CME)
CME Programs on Fulvestrant
International
Fulvestrant en Espanol Fulvestrant en Francais
Business
Fulvestrant in the Marketplace Patents on Fulvestrant
Experimental / Informatics
List of terms related to Fulvestrant

Fulvestrant
Clinical data
Routes of; administration	Intramuscular injection
ATC code	L02BA03 (WHO) ;
Pharmacokinetic data
Protein binding	99%
Elimination half-life	40 days
Identifiers
	IUPAC name 13-methyl-7-[9-( 4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]- 7,8,9,11,12,13,14,15,16, 17-decahydro- 6H-cyclopenta[a] phenanthrene-3,17-diol;
CAS Number	129453-61-8;
PubChem CID	104741;
DrugBank	APRD00654;
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C32H47F5O3S
Molar mass	606.772 g/mol

Fulvestrant, also known as ICI 182,780, and "Faslodex" is a drug treatment of hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy. It is an estrogen receptor antagonist with no agonist effects, which works both by down-regulating and by degrading the estrogen receptor.^[1] It is administered as a once-monthly injection.

Fulvestrant is marketed by AstraZeneca with the brand name Faslodex.

External links

References

↑ S. Kansra, S. Yamagata, L. Sneade, L. Foster & N. Ben-Jonathan, 2005. "Differential effects of estrogen receptor antagonists on pituitary lactotroph proliferation and prolactin release." Mol Cell Endocrinol. 2005 Jul 15;239(1-2):27-36.

Template:Sex hormones

Template:WikiDoc Sources

[1] S. Kansra, S. Yamagata, L. Sneade, L. Foster & N. Ben-Jonathan, 2005. "Differential effects of estrogen receptor antagonists on pituitary lactotroph proliferation and prolactin release." Mol Cell Endocrinol. 2005 Jul 15;239(1-2):27-36.

[1]

Clinical data

Routes of administration	Intramuscular injection
ATC code	L02BA03 (WHO)
Pharmacokinetic data
Protein binding	99%
Elimination half-life	40 days
Identifiers
IUPAC name 13-methyl-7-[9-( 4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]- 7,8,9,11,12,13,14,15,16, 17-decahydro- 6H-cyclopenta[a] phenanthrene-3,17-diol
CAS Number	129453-61-8
PubChem CID	104741
DrugBank	APRD00654
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C₃₂H₄₇F₅O₃S
Molar mass	606.772 g/mol

Fulvestrant

External links

References

Navigation menu

Search